Vanessa Vankerckhoven
CEO | Founder
Idevax
Antwerp, Belgium
I'm founder and CEO of Idevax, company active in skin drug delivery devices. I consider myself a passionate entrepreneur with a profound interest in science.
My organisation
About me
Vanessa Vankerckhoven is Founder and CEO of Idevax. She holds a PhD in Medical Sciences from the University of Antwerp, Belgium. She’s a passionate entrepreneur and also holds a position as Guest Professor at the Faculty of Medicine & Health Sciences at the University of Antwerp. She has a profound interest in vaccinology, medical microbiology, infectious diseases, oncology and medical devices.
Prior to founding Idevax, she founded Novosanis in 2013 as a spin-off from the University of Antwerp, Belgium. Novosanis is medical device company active in urine sample collection and preservation. She successfully led the company through the acquisition by Orasure Technologies Inc in Jan 2019 and remained CEO until October 2022.
She started her career as Research & Innovation Manager at the Vaccine and Infectious Disease Institute (VAXINFECTIO) at the University of Antwerp, Belgium.
My organisation
Idevax is a medical device company active in skin drug delivery devices. We're based in Antwerp & Wijnegem, Belgium. The company’s flagship product is VAX-ID, a device allowing for accurate, reliable and user-independent intradermal vaccination, or vaccination in the skin with a high ease of use. VAX-ID is an award-winning, patented device. The device is available for investigational use and CE marking as well as FDA approval is expected by the end of 2024. Key applications of the device include prophylactic and therapeutic vaccine delivery as well as immunotherapy.
Speaker sessions (1)
Tuesday, 17 September 2024
16:00 - 16:10
Skin vaccination: challenges and opportunities – Vanessa Vankerckhoven, IDEVAX
Skin vaccination offers a promising avenue in vaccine delivery. The talk will provide insights into delivery methods, immune response, stability, scalability, and regulatory hurdles, as well as clinical data.
Speaker presentation
Download speaker presentation